Medicated Feed Against Swine Parasites, Dysentery Withdrawn

Jul 12, 2023

The Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) announced on June 30 the voluntary withdrawal of the combination medicated feed containing Safe-Guard (fenbendazole) and Lincomix (lincomycin) for use in pigs. The sponsor requested the agency withdraw the application.

The fenbendazole and lincomycin combination is used for the removal of certain internal parasites, the treatment and control of swine dysentery, and reduction in the severity of swine mycoplasmal pneumonia.

Lincomycin is a veterinary feed directive (VFD) drug, meaning any use of lincomycin, alone or in a combination, in feed requires a VFD order from a licensed veterinarian.

Fenbendazole and lincomycin are marketed as separate Type A medicated articles. Fenbendazole—also known as Safe-Guard— is marketed under new animal drug application (NADA) 131-675, and lincomycin—also known as Lincomix—is marketed under NADA 097-505. NADA 140-954 provided for the combination of these two medications in swine feed.

Because this NADA 140-954 has been withdrawn, mixing these two drugs in feed is no longer permitted, and VFD orders authorizing their use in combination may no longer be issued, the FDA CVM explained on its website.

Click here to see more...

Video: Season 6, Episode 7: Takeaways from the Second International Conference on Pig Livability

This year’s conference fostered open, engaging conversations around current research in the swine industry, bringing together hundreds of attendees from 31 states and six countries. Two leaders who helped organize the event joined today’s episode: Dr. Joel DeRouchey, professor and swine extension specialist in the Department of Animal Sciences and Industry at Kansas State University, and Dr. Edison Magalhaes, assistant professor in the Department of Animal Sciences at Iowa State University. They share key takeaways from the conference, including the importance of integrating data when evaluating whole-herd livability, building a culture of care among employees and adopting new technologies. Above all, the discussion reinforces that this industry remains, at its core, a people business.